Key result
Rosiglitazone reduced neointimal hyperplasia after vascular injury, decreasing the intima/media ratio from 0.78 to 0.47 via a PKG-dependent pathway.
Rosiglitazone prevents neointimal hyperplasia after vascular injury by modulating VSMC phenotype through a PKG-dependent pathway, suggesting a potential mechanism to reduce restenosis after angioplasty.
Answers are grounded in this paper and cite their sources.
Should not change post-angioplasty practice; leaves open PKG pathway as target for human restenosis trials.
Vascular smooth muscle cells (VSMCs) undergo phenotypic changes in response to vascular injury such as angioplasty. Protein kinase G (PKG) has an important role in the process of VSMC phenotype switching. In this study, we examined whether rosiglitazone, a peroxisome proliferator-activated receptor (PPAR)-γ agonist, could modulate VSMC phenotype through the PKG pathway to reduce neointimal hyperplasia after angioplasty. In vitro experiments showed that rosiglitazone inhibited the phenotype change of VSMCs from a contractile to a synthetic form. The platelet-derived growth factor (PDGF)-induced reduction of PKG level was reversed by rosiglitazone treatment, resulting in increased PKG activity. This increased activity of PKG resulted in phosphorylation of vasodilator-stimulated phosphoprotein at serine 239, leading to inhibited proliferation of VSMCs. Interestingly, rosiglitazone did not change the level of nitric oxide (NO) or cyclic guanosine monophosphate (cGMP), which are upstream of PKG, suggesting that rosiglitazone influences PKG itself. Chromatin immunoprecipitation assays for the PKG promoter showed that the activation of PKG by rosiglitazone was mediated by the increased binding of Sp1 on the promoter region of PKG. In vivo experiments showed that rosiglitazone significantly inhibited neointimal formation after balloon injury. Immunohistochemistry staining for calponin and thrombospondin showed that this effect of rosiglitazone was mediated by modulating VSMC phenotype. Our findings demonstrate that rosiglitazone is a potent modulator of VSMC phenotype, which is regulated by PKG. This activation of PKG by rosiglitazone results in reduced neointimal hyperplasia after angioplasty. These results provide important mechanistic insight into the cardiovascular-protective effect of PPARγ. A drug developed for diabetes can also inhibit the growth of cells that elevate risk of cardiovascular disease, researchers in Korea have found. Blood vessels are formed primarily from vascular smooth muscle cells (VSMCs). When vascular damage occurs, once-quiescent VSMCs begin to proliferate, forming circulation-blocking scar tissue and laying the foundation for atherosclerosis. Led by Hyo-Soo Kim at Seoul National University, the researchers examined whether this transition is affected by rosiglitazone, an insulin-sensitizing drug that also exerts cardiovascular effects. They determined that rosiglitazone prevents VSMCs from entering this proliferative stage. It does so by boosting the activity of protein kinase G, a signaling factor known to control VSMC behavior. Importantly, rosiglitazone also prevented scar tissue formation in a rat model of angioplasty surgery, indicating a potentially promising mechanism for reducing risk of cardiovascular injury.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2013) studied Neointimal hyperplasia after vascular injury (n=20). Rosiglitazone vs. Vehicle was evaluated on Intima/media ratio at 2 weeks after vascular injury (p=<0.05). Rosiglitazone reduced neointimal hyperplasia after vascular injury, decreasing the intima/media ratio from 0.78 to 0.47 via a PKG-dependent pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: